Suggested remit: To appraise the clinical and cost effectiveness of lasmiditan within its marketing authorisation for treating acute migraine.
Status In progress
Decision Selected
Process STA 2018
ID number 3759

Provisional Schedule

Expected publication 29 March 2023

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
26 March 2021 The Department for Health and Social Care has asked NICE to conduct an appraisal of Lasmiditan within its marketing authorisation for treating acute migraine. Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-May 2022. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
26 March 2021 In progress. Topic is in progress
21 January 2021 - 18 February 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual